Toragen, Inc. Announces the Appointment of Board of Directors and Senior Staff
Retrieved on:
Monday, August 15, 2022
Biotechnology, Pharmaceutical, Health, Oncology, 21st Century Fox, California State University, Radiation, University of California, San Diego, Senior, CFO, Takeda Oncology, Investment, Dog, Board, UC, Cancer, University, Therapy, Company, Portola Pharmaceuticals, Research and development, Associate, Biotechnology, CPA, Rock Ventures, VP, Doctor of Philosophy, NASDAQ, Applied science, Accounting, Paul F. O'Rourke, HPV, Pharmaceutical industry, Geology, MD, Biochemistry
Additionally, Toragen announced the appointment of Cheryl Collett as CFO, effective June 20, 2022, and Dr. Richard Lumpkin as Director, Research & Development, effective July 1, 2022.
Key Points:
- Additionally, Toragen announced the appointment of Cheryl Collett as CFO, effective June 20, 2022, and Dr. Richard Lumpkin as Director, Research & Development, effective July 1, 2022.
- In 1960, he started the first cattle-feeding operation in Texas and grew the company to become the largest cattle-feeding company in the world.
- He remains actively involved in investments and philanthropic activities of his private foundation, the Paul F. and Virginia J. Engler Foundation.
- Dr. Lumpkin previously served as Senior Director at Global Blood Therapeutics becoming the first employee of this Third Rock Ventures founded company.